Eikon Therapeutics, Inc. 8-K

What Happened
Eikon Therapeutics, Inc. filed an 8-K on February 6, 2026 reporting that it amended and restated its certificate of incorporation and adopted amended and restated bylaws effective immediately prior to the closing of its initial public offering (IPO). The Restated Certificate was filed with the Delaware Secretary of State and the Restated Bylaws were adopted effective February 6, 2026. The board of directors and the company’s stockholders previously approved both documents.

Key Details

• Effective date: February 6, 2026 (immediately prior to IPO closing).
• Restated Certificate of Incorporation filed with the Delaware Secretary of State.
• Restated Bylaws adopted and effective as of Feb 6, 2026; both were previously approved by the board and stockholders.
• Documents are filed as Exhibits 3.1 and 3.2 to the 8-K; report signed by CEO Roger M. Perlmutter.

Why It Matters
These filings establish Eikon’s public-company charter and governing rules following the IPO. The amended certificate and bylaws set the legal framework for governance, shareholder rights and corporate procedures going forward. Investors who want to understand any changes to voting rights, board structure, transfer restrictions or other corporate rules should review the Restated Certificate and Restated Bylaws (Exhibits 3.1 and 3.2) filed with the 8-K.